A Phase 2 Challenge Study with Monovalent Norovirus Vaccine
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2018
At a glance
- Drugs Norovirus Vaccine-Vaxart (Primary)
- Indications Norovirus infections
- Focus Therapeutic Use
- Sponsors Vaxart
- 09 Nov 2018 According to a Vaxart media release, due to a manufacturing issue, the norovirus GI.1 vaccine tablets failed release testing and the company now expect to initiate this phase 2 monovalent challenge study in the first half of 2019.Vaxart is working diligently to resolve the issue.
- 02 Nov 2017 New trial record
- 30 Oct 2017 According to an Aviragen Therapeutics media release, this study is expected to begin in the second half of 2018.